SCHEMBL6926756

SCHEMBL6926756

CN1CCN(c2ccc(-c3nc(-c4ccc(F)cc4)c[nH]3)cn2)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDO2 P48775 2/20 0.58
HDAC10 Q969S8 1/20 0.49
ALK Q9UM73 3/20 0.46
DGAT1 O75907 1/20 0.46
SOAT1 P35610 1/20 0.46
KCNH2 Q12809 1/20 0.46
TNKS O95271 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
HTR3A P46098 1/20 0.43
FYN P06241 2/20 0.42
IL2 P60568 1/20 0.42
MAP4K1 Q92918 1/20 0.42
HTR1A P08908 1/20 0.42
DRD4 P21917 1/20 0.42
HTR2A P28223 1/20 0.42
SLC6A4 P31645 1/20 0.42
DRD3 P35462 1/20 0.42
TLR9 Q9NR96 1/20 0.41
TLR8 Q9NR97 1/20 0.41
TLR7 Q9NYK1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6925451 0.89 FYN (0.54) TDO2DGAT1SOAT1KCNH2TNKS
SCHEMBL6927440 0.88 HRH4 (0.51) TDO2ALKDGAT1SOAT1KCNH2
SCHEMBL6923619 0.88 DRD3 (0.47) TDO2HDAC10ALKHTR1ADRD4
SCHEMBL6925946 0.87 TDO2 (0.45) TDO2L3MBTL1HTR1ADRD4HTR2A
SCHEMBL6924654 0.86 HDAC1 (0.50) TDO2HDAC10KCNH2HTR3AIL2
SCHEMBL6925583 0.85 HTR2A (0.47) TDO2HTR1ADRD4HTR2ASLC6A4
SCHEMBL6927588 0.85 DRD3 (0.47) TDO2HDAC10L3MBTL1MAP4K1HTR1A
SCHEMBL6925048 0.85 TDO2 (0.43) TDO2HDAC10ALKDGAT1KCNH2
SCHEMBL6927079 0.84 TDO2 (0.43) TDO2HDAC10HTR1ADRD4HTR2A
SCHEMBL6924520 0.83 CNR2 (0.51) TDO2ALKDGAT1SOAT1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6514966-B2 Neuropeptide Y antagonists such as 2-chloro-5-(4-(3,4-dich loro-phenyl)-1H-imidazol-2-yl)-pyridine PFIZER INC. 2003-02-04 US disclosed
US-6355635-B1 IMIDAZOLEBENZENE, IMIDAZOLEPYRIDINE COMPOUNDS FOR TREATMENT OF OBESITY PFIZER INC. 2002-03-12 US disclosed
US-20010039277-A1 Compounds for the treatment of obesity ELLIOTT RICHARD L (US) 2001-11-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010039277-A1 Compounds for the treatment of obesity NPY1R, NPY4R, NPY2R TDO2 1269/4885HDAC10 1037/4885ALK 4619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.